Study study type PathologyT1T0Patientssample sizesROB Results

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus placebo
pembrolizumab alone
KEYNOTE-522, 2020
  NCT03036488
RCTes-BC - TNBC - NA - all populationpembrolizumabplacebopreviously previously untreated, nonmetastatic disease, stage II or stage III, triple-negative breast cancer treated with paclitaxel and carboplatin, treated for neoadjuvant phase and an adjuvant phase;784 / 390low
conclusif
  • demonstrated 12.6-fold increase in pCR (PE)
  • suggested 37 % decrease in events or deaths (EFS) (PE)